Contact Us

ReNu Contact Solution
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Parker & Waichman, LLP Announces It Has Been Retained by Plaintiff Diagnosed With Fusarium Keratitis in Left Eye After Using ReNu Contact Lens Solution With MoisturLoc

Victim Underwent Cornea Transplant, Lensectomy, Capsulectomy, Iris Removal and Multiple Flush-Out Surgeries on Left Eye, Awaits FDA Approval for Iris Transplant

Apr 13, 2006 | PrimeZone

Parker & Waichman, LLP (http://www.yourlawyer.com) announced that it has been retained by a 53-year-old man who was diagnosed with fusarium keratitis after using ReNu Contact Lens Solution with MositurLoc, manufactured by Bausch & Lomb, Inc. (NYSE:BOL).

On April 10, 2006 the FDA and the CDC issued public health warnings concerning serious fungal infections associated with contact lens use, and announced that Bausch and Lomb agreed to stop shipping the ReNu MoistureLoc brand contact lens solution. The CDC stated that it had interviewed 30 patients suspected of having fungal keratitis. Of these 30 patients, 28 wore soft contact lenses and 26 used Bausch & Lomb ReNu contact lens solution in the month prior to the fungal infection diagnosis. For more information on ReNu with MoisturLoc contact lens solution and fungal keratitis please visit http://www.yourlawyer.com/topics/overview/renu_contact_solution and http://www.renulawsuit.com.

The victim, who resides in upstate New York, was diagnosed with a fungal infection in his left eye in October 2005, and was sent to a cornea specialist at Columbia Presbyterian in New York City. The specialist performed a corneal confocal microscope exam and performed several biopsies, which confirmed the diagnosis of fusarium keratitis. The specialist notified the plaintiff that a cornea transplant would be necessary. The transplant procedure could not be performed until the infection was under control, thus the victim was prescribed voriconazole, a potent anti-fungal medication, which had to be administered approximately every 2 hours, 24 hours each day, over the course of several months. After the infection appeared under control, the cornea transplant procedure was performed. During the cornea transplant surgery, additional signs of the fungal infection were discovered. This later led to approximately 5 flush-out surgeries, which involved accessing the back of the left eye through an incision in order to remove additional evidence of the fusarium fungal infection. The infection returned following the flush-out surgeries, requiring the victim to undergo a lengthy and invasive surgery with the following procedures performed on his left eye: lensectomy, capsulectomy, removal of iris, removal of vitreous fluid and the removal of the fungal infection. The victim is left with only 15% vision in his left eye and is currently awaiting FDA approval for an iris transplant.

Fungal keratitis is a severe infection of the cornea. Risk factors for infection usually include trauma (generally with plant material), chronic ocular surface diseases, immunodeficiencies, and, rarely, contact lens use. An estimated 30 million persons in the United States wear soft contact lenses; the annual incidence of microbial keratitis is estimated to be 4 -- 21 per 10,000 soft contact lens users. Fungal keratitis is a condition more prevalent in warm climate. First-line treatment includes topical and oral antifungal medications; patients who do not respond to medical treatment usually require surgical intervention, including corneal transplantation. These infections are not transmitted from person to person.

About Parker & Waichman, LLP

Parker & Waichman, LLP is a leading products liability and personal injury law firm that represents plaintiffs nationwide. The firm has offices in New York and New Jersey. Parker & Waichman, LLP has assisted thousands of clients in receiving fair compensation for injuries resulting from defective medications and medical devices. For more information on Parker & Waichman, LLP please visit: (http://www.yourlawyer.com) or call 1-800-YOURLAWYER (1-800-968-7529).

CONTACT: Parker & Waichman, LLP
         Jason Mark, Esq.
         Melanie H. Muhlstock, Esq.
         1-800-YOURLAWYER
         1-800-968-7529 -- toll-free
         info@yourlawyer.com
         http://www.yourlawyer.com


Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo